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Abstract
In order to approach human cancer immunotherapy, the author carried out the immunotherapy
with BCG on mice having homotransplanted cancer, observed the posttransplantation results with
lapse of time, conduced daily macrophage inhibition test (MI test) and found the immunotherapy
to be effective. At the same time the MI test proved to be a useful criterion in determining the
course of cancer progress and effectiveness of the immunotherapy.
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Abstracts. In order to approach human cancer immunotherapy,
the author carried out the immunotherapy with BeG on mice having
homotransplanted cancer, observed the posttransplantation results
with lapse of time, conducted daily macrophage inhibition test (MI
test) and found the immunotherapy to be effective. At the same time
the MI test proved to be a useful criterion in determining the course
of cancer progress and effectiveness of the immunotherapy.
The immunotherapy is the fourth therapeutic method following the sur-
gical treatment, radiotherapy, and chemical treatment, and it has recently
attracted a great interest. In order to attain effective results by immuno-
therapy it is necessary to demonstrate the tumor specific antigen (TSA) , i.e.
cancer cell antigen that elicits an immune reaction in vivo (1). Ever since
Foley's (2) discovery (1953) of tumor antigen in the autogenous cancer of
animal induced by methylcholanthrene, Habel (3) has demonstrated tumor
antigen in virus-induced tumor, Klein (4) in human lymphoma cells, and
Hellstrom et al. in colon and kidney cancers (5, 6). However, even if there
exists cancer specific antigen, the immune reaction does not occur unless the
host recognizes it. And as the induction methods of cancer specific immunity,
there have been reported such methods as transplantation and removal (i.e.,
extirpation or ligation) of primary or autogenous cancer and of homogenic
cancer, transplantation of modified auto-homogenic cancer, and transplantation
of modified auto-homogenous cancer cells previously treated with radiation or
anticancer agents.
On the other hand, the nonspecific immunologic stimulus represented by
BeG is thought to enhance general immune reactivity of cancer-bearing body
and also to induce ultimately a cancer specific immunity. For the past half a
century BeG has been essentially considered as a vaccine for tuberculosis treat-
ment, and widely used in the world. Since reports of Halpern (7) and Lemond
(8) stating that, after the BeG inoculation, the reticuloendothelial system can be
stimulated due to the proliferation of transplanted tumor, Mathe (9) yielded
197
1
Hayashi: Experimental studies of tumor immunotherapy. II. Tumor
Produced by The Berkeley Electronic Press, 1976
198 S. HAYASHI
more effective results by smearing fresh BOG suspension over the scratch made
on the skin, as compared with untreated control group. Morton (10) injected
BOG into melanoma-bearing patients who were not indicated for surgical treat-
ment, and observed the shrinkage of the half number of tumors so treated. In
addition Zbar (11) et ai. found the antitumor effect of BOG on the syngeneic
hepatocarcinoma induced artificially in guinea pigs by administering diethyl
nitrosamin. Tanaka (12) and Tokunaga (13) also reported the results obtained
with mice and guinea pigs.
Up to date, concerning the methods of using BOG in the immunotherapy
for human and animal cancers, there have been (1) its inoculation into the skin
of cancer-bearing body, (2) its injection into solid tumor, (3) the intradermal
injection of cancer cells with BOG, and (4) oral administration. Regarding the
method and time of administration or effective duration of such injection,
however, opinions are varied and also sufficient investigations remain to be
carried out.
In the present study the author carried out the immunotherapy with BeG
on mice having homotransplanted cancer, observed the post-transplantation
results with lapse of time, conducted daily macrophage inhibition test (MI test)
and found the immunotherapy to be effective. At the same time the MI test
proved to be a useful criterion in determining the course of cancer progress and
effectiveness of the immunotherapy.
MATERIALS AND METHODS
a. Animals: Animals used were C3HjHe mice weighing about 20g and
purchased from the Fujii Medico-chemical Test Animal Dealers. They were
fed on solid Oriental food, and tap water was given ad libitum. Guinea pigs
weighing 200-300g were also purchased from the same dealers and were fed on
rice bran mixed with solid Oriental food.
b. Test tumor: Tumor used was ascites hepatoma 134 (MH 134); this has
been derived from C3H mouse obtained from Tokyo Medical Laboratory, and
maintained successively in the peritoneal cavity of C3H mice as ascites until use.
c. BeG: BCG used was obtained from Japan BCG Manufacturing Com-
pany in a frozen-dried state, which was dissolved in saline solution before use.
d. The preparation of lymphocytes of mouse: Mice were sacrificed in an ether
bottle. Axillay lymph nodes from both sides were taken out asceptically, which
were washed with saline solution, and sliced into fine pieces with scissors.
These pieces were immersed in 5ml physiological saline to make a lymphocyte
suspension, which was left standing at room temperature for 30 min then passed
through an SO-mesh filter, and centrifuged at lOOOr.p.m. for lOmin. After re-
peating the centrifugation, the sediment was suspended in TC-199 solution for
the experiment.
e. Preparation of macrophages: Twenty to thirty ml of fluid paraffin sterilized
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by high pressure is injected into the peritoneal cavity of guinea pigs 4-5 days
prior to the preparation of macrophages, and the animals are sacrificed by
severing the cervical artery. Then the peritoneal cavity is opened, the cavity
is washed with lOO-15Oml saline solution, and the cell-containing abdominal
fluid is collected in a centrifuge tube. This fluid is centrifuged at lOOOr.p.m.
for 5min, and then paraffin of the upper layer is removed by sucking. The
residue is washed again with saline solution, centrifuged once more at 1000
r.p.m. for 5 min, and suspended in TC-199 solution for the experiment.
f. Preparation of antigen solution: MH 134 is suspended in TC-l99 medium,
adjusting the cell concentration to 107 cells/ml, supersonicated at 150 rnA for
5 min, and then centrifuged at 3000 r.p.m. for 20 min. The supernatant is taken
as the antigen solution; this is sealed into ampules, each of which is made to
contain 0.5ml antigen solution, and such ampules are kept at -20°C before use.
This solution contains protein in the concentration of 2mg/ml, which is diluted
20-fold before use. Namely, the protein concentration of antigen solution in
the MI test is adjusted to 100,ug/ml. At this concentration there occurs no non-
specific migration inhibition of macrophages.
g. Measuring of MI activity: As already described in Part I, the MI activity
measurements are taken by the capillary tube direct method, where lympho-
cytes and macrophages are mixed in the ratio of 1 : 5, and centrifuged at 1000
r.p.m. for 5min. The sediment so obtained is put into capillary tubes, one end
of which is sealed with open end up. These tubes are centrifuged at 800 r.p.m.
for 3min, and are cut with an ampule cutter at the boundary line between the
supernatant and the cell layer. The tubes containing the cell layer are fixed
with silicon glass onto a small Petri dish, approximately one cm in diameter, the
bottom of which is covered with a pi~ce of round coverglass. Such small Petri
dishes are divided into antigen-containing and nonantigen-containing groups,
then covered with coverglasses, and incubated in an incubator containing 5%
CO2 gas at 37°C for 24 hr, and then the migration areas are measured. The
long diameter x short diameter of the cell area, in which the cells have migrat-
ed from the cut-end of the capillary tube, is taken as the migration area, and
the ratio of the antigen containing group to that of non-antigen group is taken
as the migration index (MI). And those that gave the ratio below 85% are
taken as positive.
Experiment 1. Two weeks after subcutaneous injection of 2x 104 MH-134
cells on the back of C3H mice, these animals were divided into 4 groups; the
number of mice in each group was 6: (l) receiving the injection of 0.1 ml saline
solution; (2) receiving 0.04 mg/OJ ml BCG; (3) receiving O.4mg/O.1 ml BGG: and
(4) receiving 4mg/OJ BGG. Saline solution or BCG was injected directly into
the tumors. Survival time and tumor growth were observed on each group. In
addition, on groups (1) and (4) the MI activity of regional lymph-node cells was
measured with lapse of days.
Experiment 2. C3H mice were transplanted with 2x 104 MH.I34 cells sub.
cutaneously on the back, and these were divided into 5 groups; the number of
mice in each group was 10: (1) non-treated control group; (2) group receiving
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4mg BCG and 2x 104 MH-134 cells one week later on the loin away from
tumor; (3) group receiving an additional 4mg BCG plus 2x 104 MH-134 cells
one week after (2); (4) group receiving 4mg BCG and 2x 104 MH.134 cells two
weeks later on the loin away from the tumor; and (5) group receiving an addi.
tional4mg BCG plus 2x 104 MH-134 cells two weeks after (4). The survival
time and the tumor growth were observed on these five groups, and also MI
activity was measured daily.
E'lCperiment 3. C3H mice were transplanted subcutaneously on the back
with 2x 104 MH-134 cells, and were divided into 5 groups; the number of mice
in each group consisted of 10: (1) non-treated group; (2) the group of which
tumor was extirpated on the second week; (3) the group in which tumor was
removed on the second week and 4mg BCG was injected at a site away from
the tumor site; (4) the group in which tumor was removed on the second week
and 2x 104 MH-134 cells previously treated with mitomycin C was injected at a
site away from the tumor site; and (5) the group in which tumor was removed
on the second week and the combination of 4mg BCG plus 2x 104 MH-134 cells
previously treated with mitomycin C was injected at a site away from the
tumor site. Tumor growth and survival time of these five groups were observed,
and simultaneously MI activity of the axillary lymph node cells was measured
with lapse of days. As for mitomycin C the cells were treated with 25 pg/ml
for 30min at room temperature.
RESULTS
Exp. 1. In the (1) control group tumor was palpable around one week
and grew rapidly after two weeks, and about half the animals died by the 24th
day, the average survival time being 26 days. In the (2) group the proliferation
of tumor was slower than that of the (1) group, the average survival time being
prolonged to 29.6 days. The proliferation curve of the (3) group was slower
than that of the (2) group, the average survival time being 33.5 days. The (4)
group showed the slowest growth as compared with other groups, the average
survival time being 34.2 days. (Fig. 1).
Concerning the MI activity, the (1) group became positive by the third
day, reached the maximum of 66% on the sixth day, decreased gradually
thereafter, and became negative from the second week. The (4) group reached
its peak on the sixth day and then decreased, whereas by BCG injection into
the tumor, MI activity again reached the maximum of 60% on the 17th day
(namely, on the fourth day after BCG injection), thereafter decreased gradually
and disappeared (Fig. 2).
Exp. 2. The average survival time was 29 days in (1) group, 36.3 days
in (2) group, 43.3 days in (3) group, 31.6 days in (4) group, and 34.5 days in
(5) group, while the 50% survival time was 31 days in (1) group, 34.5 days in
(2) group, 40 days in (3) group, 33 days in (4) group, and 36 days in (5) group.
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Fig. 1. Tumor growth and survival time after intra-tumor BOG injection.
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Fig. 2. Macrophage migration inhibition activity and tumor growth after intra-tumor
injection of BOG.
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The group of which average survival time was longest was (3) group that
received immunization at an interval of a week twice, and the average survival
time in (5) group was less than that of (2) group.
As for the MI activity, it reached its maximum on the sixth day in (1)
group, gradually decreased thereafter and disappeared by the second week. In
(2) group, the activity once tended to decrease after the injection but reached
again its peak of 59% by the 14th day (the seventh day after injection), decreased
graduadually thereafter, and turned negative on the 21st day. Compared with
the control group the positive period is 7 days longer. In (3) group which
received its second injection on the 14th day, MI activity decreased more slowly
than in (2) group and became negative on the 29th day, showing the positive
period 8 days longer than (2) group (Fig. 3). In (4) group, the activity appeared
to reach its peak of 60% on the 17th day (on the third day after injection),
decreased gradually thereafter, and turned negative on the 23rd day. This is
a prolongation of 9 days as compared with control group. In (5) group in
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Fig. 3. Effect of immunotherapy on MI activity and survival time of tumor bearing mice.
CD first immunotherapy treatment
® second immunotherapy treatment
·.. ···0··· .. · control
-,-6-,- response to first treatment
-0- response to second treatment
6
Acta Medica Okayama, Vol. 30 [1976], Iss. 3, Art. 5
http://escholarship.lib.okayama-u.ac.jp/amo/vol30/iss3/5
Experimental Studies of Tumor Immunotherapy 203
which the second injection was done on the 28th day, MI activity did not be-
came positive (Fig. 4).
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Fig. 4. Effect of immunotherapy on MI activity and survival time of tumor bearing
mice.
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Exp. 3. In (I) control group, tumor began to be palpable as a solid node
by about the 7th day and grew rapidly by about the second week. MI activity
reached its highest by the sixth day, gradually diminished along with the
tumor enlargement, and turned negative by about the second week. The 50%
survival time of this group was 24 days. In the group of (2) where tumor had
been extirpated in the second week, MI activity turned negative after the tumor
removal, then returned positive again by about the 20th day, persisted for 3 to 4
days and finally turned negative. Tumor recurred one after another a few
days later. In (3) group, MI activity did not grow stronger even after BeG
injection, and the 50% survival time of this group was 47 days. In (5) group,
MI activity had disappeared once in the second week, then slightly later than
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(2) group, i.e., around 20 days later, became positive for a long period of about
15 days. During this period no recurrence of tumor was seen, and after the
MI activity had turned negative there was recurrence in two out of ten mice,
although the proliferation was very slow. The 50% survival time of this group
was 93 days, showing an extensive prolongation as compared with other groups
(Fig 5).
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Fig. 5. Effcct of tumor extirpation and immunotherapy on MI activity and survival
time of tumor bearing mice.
CD .... ···· ....0 control group
® - - - -6 tumor extirpation group
® _·-·_·-0 extirpation plus BCG injected group
@ A extirpation plus MMC treated MH-134 injected group
® ---. extirpation plus BCG plus MMC treated MH-134 injected group
DISCUSSION
Inhibition of the cell migration by antigen in vitro was first studied by
Rich and Lewis (14) on explants of lymphoid tissue maintained in culture.
This and subsequent work have shown that inhibition of cell migration depends
upon the existence of delayed hypersensitivity of host, and the effect is seen
only with lymphoreticular tissue. The capillary tube technique developed by
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George and Vaughan (15) permitted a more analytical approach, both quanti-
tatively and in the identification of the cell types affected. With this technique,
David et ale (16) have demonstrated reactivity to bacterial antigens, proteins and
haptens which paralleled skin reactivity to these antigens in vivo.
Bloom and Bennett (17) and David (16) have independently found that,
through interaction by specific antigens, lymphoid cells obtained from animals
with delayed hypersensitivity release a substance that inhibits migration of
macrophages from normal as well as from hypersensitive animals. David has
also shown that inhibition does not occur if syntheses of protein or messenger
ribonucleic acid are blocked by puromycin or actinomycin-D respectively. Now,
in Exp. 1 when BCG is injected into tumor, specific inflammatory reaction of
BCG enfolds tumor cells nonspecifically and destroys them, in other words, by
the so-called enfolding effect, sensitized lymphocytes (T-cells) are reinforced as
to yield an antitumor effect, which revives the MI activity once on the verge
of disappearance. Even the average survival time is lengthened by 8 days, in-
dicating BCG to be effective as antitumor action. In addition, when BOO is
injected directly into the tumor, tumor-growth inhibitory effect and survival
effect show BCG dose-response, and the administration of BCG in the doses of
0.04, 0.4 and 4 mg reinforces its effect in the order mentioned. Moreover,
when the combined BOO and tumor cells are injected at a site away from the
tumor focus (that is, when BOG adjuvant therapy is performed), though
inferior to direct injection into tumor, a fairly good antitumor effect can be
attained, and even in MI activity its positive period is lengthened by about one
week. From the results of Exps. 1 and 2, the BOG adjuvant therapy, in which
BCG is injected at a site a little distant from pathologic focus rather than
directly into the tumor, enhances the cancer immunity of tumor-bearing mice,
has been clarified to inhibit the proliferation of main pathologic focus, and also
gives us a hope in the prevention of postoperative recurrence and the prolifera-
tion-inhibion of metastatic residual focus. The BOG adjuvant therapy rein-
forces this MI activity, in other words, it enchances specific cellular immunity.
Regarding the optimal concentration of tumor antigen, the problem was already
described in the previous paper. And MI activity was measured on regional
lymph node cells of the mice which were previously treated with mitomycin 0
subcutaneously on the back to inhibit the proliferation of tumor cells; and then
tumor cells were injected into the animals in step-wise doses. The group
receiving 105 tumor cells showed the highest MI activity, while the groups re-
ceiving the dose of 10 3 and 108 tumor cells hardly showed positivity. This
phenomenon seems to suggest that for the MI activity to be positive presence
of the tumor cells in vivo have a certain latitude, beyond which or below which
it turns negative. In order to apply this fact and the BOG adjuvant therapy
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after surgical operation, Exp. 3 was conducted. In (1) group, after tumor
transplantation the MI activity of regional lymph-node cells was positive already
on the third day, reached its maximum on the sixth day, thereafter decreased
gradually and turned negative in the second week. The tumor proliferation
rapidly gains its speed for past two weeks when MI activity turns negative. And
when this result is compared with the previous results (Part 1), the positive
period of MI activity corresponds to the period during which the number of
tumor cells is limited to a certain number. And when the tumor cells proli-
ferate beyond a certain limit, the MI activity also seems to disapppear. In (2)
group where tumor was extirpated in the second week, the activity of MI once
lost became positive again one week later and turned negative again 3-4 days
later. The :recurrence of tumor could be recognized macroscopically another 4
to 5 days later, and at least during the period when MI activity was positive,
no recurrence of tumor could be observed. Therefore in order to check the
recurrence or eliciting the proliferation inhibition most effectively, it would be
necessary to maintain MI activity as long as possible; that is, to administer the
tumor antigens of which cell division has been inhibited. However, as observed
in the (3) and (4) groups by the subcutaneous injection of tumor antigens alone
or BCG alone, no any marked effect could be observed on the survival time or
on reinforcement of MI activity. It seems that by the coexistence of tumor
antigen and BCG the antigenity is transmitted and strengthened in vivo, and also
BCG, as a nonspecific stimulant, plays a role of the specific stimulant through
contact with antigens. The author observed that MI activity can be reinforced
and maintained and observed the inhibition of tumor recurrence as well as the
prolongation of survival time in the mice extirpated of tumor, when the com-
bination of BCG and MH-134 cells, of which proliferation had been inhibited
by mitomycin-C treatment, was injected into the mice. This indicates the
possibility in clinical practice that the immunotherapy would yield favorable
results in the recurrence of cancer and the prognosis after the removal of
tumor. For such a purpose it would be advisable to follow up the specific
cellular immunity as represented by the MI-test.
Nevertheless, in the postoperative treatment of cases with malignant tumor
there remain problems as regards the immunotherapy on every patient, and the
BCG adjuvant therapy might not get expected good results on absolutely non-
curative patients. In Exp. 2 the average survival time was prolonged in the
groups of (3), (2), (5), (4) and (1), in that order. And the group receiving
immune sensitization twice on the 14th and 28th days after tumor transplanta-
tion give the poorer results than the group sensitized once only. Even from the
aSPect of MI activity, (5) group sensitized twice does not acquire positive MI
activity, indicating a limitation in immunotherapy in the cases of the terminal
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stage of cancer. In the group sensitized in a relatively early stage of the first
week, especially in (3) group sensitized consecutively twice, the survival time
is prolonged as much as 14 days in comparison with (1) control group, indicat-
ing that early frequent immunization is effective. These findings seem to sug-
gest that the immunotherapy is indicated for those cases after radical operation
or those in the condition close to it; namely, in the state of the minimum
residual tumor tissue.
Surgical biochemical, and radiation therapies are carried out for the pur-
pose of eradicating or destroying cancer cells, but it is difficult to annihilate
completely cancer cells to the very last one. Hence it is suggested that specific
immunotherapy is a choice effective for those cases after surgical therapy.
Furthermore, chemotherapy and radiation therapy so damage normal cells to a
high percentage that even on this point alone the immunotherapy is superior.
However, when applying it in clinics after surgical operation, depending on
the histological type of cancer and also the difference in antigens, it is necessary
to carry out further studies as to the method of immunotherapy te be employed
and the number of times of the immunotherapy to be given.
Recently there are reports stating that, in the patients whose immunity is
low, BOG live bacteria elicit infection-like symptoms or anaphylaxis-like shock.
And for an improved method on overcoming these dangers, peptide glycolipids
that constitute the cell wall (18) and skeleton of BOG are attracting attention.
Such problems of bacterial components would be further studied for the future
clinical application of this immunotherapy.
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